| Acquired by | GlaxoSmithKline |
| Price | $720M |
| Date | 4/08 |
| Terms | Cash |
| Website | sirtrispharma.com |
| Category | Biotech |
| Phone | 617-252-6920 |
| info@sirtrispharm... | |
| Employees |
| Total | $82M |
| Seed | $5M |
| Series A, 12/04 Wellcome Trust Polaris Venture Partners Techno Venture Management Cardinal Partners Skyline Ventures | $13M |
| Series B, 3/05 Three Arch Partners Cargill Ventures Polaris Venture Partners Techno Venture Management Wellcome Trust Cardinal Partners | $27M |
| Series C, 4/06 Bessemer Venture Partners Genzyme Ventures | $37M |
Sirtris Pharmaceuticals (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes.
via: Sirtris
